▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] The Korean market operator’s decision to delist a local pharmaceuticals company is raising questions about the fairness in authorities’ action against firms accused of accounting erro...
[THE INVESTOR] Samsung Bioepis’ Imraldi, a biosimilar for Humira, has earned more than 60 percent of the market in Germany, solidifying its landing in the European market, industry data indicated on...
[THE INVESTOR] The Korea Exchange, the operator of the nation’s equity market, seeks to review this week the accounting misconduct of the country’s second-largest biotech company by market cap, whic...
[THE INVESTOR] Samsung BioLogics said on Dec. 5 it has signed a contract with Saint-Gobain for supply of single-use biopharmaceutical manufacturing equipment. Under the deal, the French firm will s...
[THE INVESTOR] Korean biotech firm Hugel said on Dec. 4 that its botulinum toxin Botulax has received marketing approval from Taiwan’s Ministry of Health and Welfare. Shares of Hugel rose 3.85 perc...
[THE INVESTOR ] Celltrion said on Dec. 2 that the European Medicines Agency has accepted its application for marketing authorization to a subcutaneous version of Remsima, its biosimilar of autoimmun...
[THE INVESTOR] Samsung BioLogics CEO Kim Tae-han reaffirmed key shareholders on Nov. 30 that the company’s accounting practice was legitimate, seeking a court injunction to nullify disciplinary acti...
[THE INVESTOR] Celltrion said on Nov. 29 it has obtained marketing authorization from the US Food and Drug Administration for Truxima, its copy version of Roche’s Rituxan (rituximab), to treat non-H...
[THE INVESTOR] Samsung BioLogics said on Nov. 28 it has filed an administrative lawsuit against a recent ruling by the country‘s financial regulator that the company violated accounting rules. T...
[THE INVESTOR] Korean display module firm Enerzent said on Nov. 22 it has signed an engineering, procurement and construction contract with US-based Micronoc for the design of energy consumption sol...
[THE INVESTOR] The growth of digital health care industry in Korea is being hindered by red tape in personal medical data and telemedicine sectors, a group of startups said on Nov. 22. The Asan Nan...
[THE INVESTOR] Celltrion refuted on Nov. 21 a news report that founder and Chairman Seo Jung-jin threw his weight around and abused a flight attendant last week. This follows a report by local cabl...
[THE INVESTOR] Korea’s iNtRon Biotechnology said on Nov. 20 it has clinched a deal with Switzerland-based Roivant Sciences to out-license SAL200, an investigational biologic for the treatment of inf...
[THE INVESTOR] Kolon Life Science said on Nov. 19 it has entered an agreement with Mundipharma to license out Invossa, its gene therapy designed to treat osteoarthritis, for the Japanese market, in ...
[THE INVESTOR] Korea’s leading biosimilar manufacturer Celltrion said on Nov. 19 that it has won approval from the US Food and Drug Administration for its tablet for treating HIV in the United State...
Samsung to ramp up Galaxy Fold production
Woongjin defers final bid for Coway to Oct.
Sae-A to acquire fiberboard maker Tailim Packaging
Video-streaming war heats up in S. Korea
YG faces W6b tax penalty as Burning Sun scandal unfolds
Aveva to upgrade integrated industrial software in digital push
Ghost Kitchen secures additional W9.2b
Medytox invests in US startup LifeSprout
September 18, 2019
